BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 37633047)

  • 1. Small molecule nitroalkenes inhibit RAD51-mediated homologous recombination and amplify triple-negative breast cancer cell killing by DNA-directed therapies.
    Hong L; Braden DC; Zhao Y; Skoko JJ; Chang F; Woodcock SR; Uvalle C; Casey A; Wood K; Salvatore SR; Asan A; Harkness T; Fagunloye A; Razzaghi M; Straub A; Spies M; Brown DD; Lee AV; Schopfer F; Freeman BA; Neumann CA
    Redox Biol; 2023 Oct; 66():102856. PubMed ID: 37633047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small molecule nitroalkenes inhibit RAD51-mediated homologous recombination and amplify triple-negative breast cancer cell killing by DNA-directed therapies.
    Hong L; Braden DC; Zhao Y; Skoko JJ; Chang F; Woodcock SR; Uvalle C; Casey A; Wood K; Salvatore SR; Asan A; Harkness T; Fagunloye A; Razzaghi M; Straub A; Spies M; Brown DD; Lee AV; Schopfer F; Freeman BA; Neumann CA
    bioRxiv; 2023 Aug; ():. PubMed ID: 37645906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Electrophilic fatty acids impair RAD51 function and potentiate the effects of DNA-damaging agents on growth of triple-negative breast cells.
    Asan A; Skoko JJ; Woodcock CC; Wingert BM; Woodcock SR; Normolle D; Huang Y; Stark JM; Camacho CJ; Freeman BA; Neumann CA
    J Biol Chem; 2019 Jan; 294(2):397-404. PubMed ID: 30478172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.
    Mani C; Jonnalagadda S; Lingareddy J; Awasthi S; Gmeiner WH; Palle K
    Breast Cancer Res; 2019 Sep; 21(1):104. PubMed ID: 31492187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.
    Mo W; Liu Q; Lin CC; Dai H; Peng Y; Liang Y; Peng G; Meric-Bernstam F; Mills GB; Li K; Lin SY
    Clin Cancer Res; 2016 Apr; 22(7):1699-712. PubMed ID: 26546619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
    Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
    Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nitro-fatty acid inhibition of triple-negative breast cancer cell viability, migration, invasion, and tumor growth.
    Woodcock CC; Huang Y; Woodcock SR; Salvatore SR; Singh B; Golin-Bisello F; Davidson NE; Neumann CA; Freeman BA; Wendell SG
    J Biol Chem; 2018 Jan; 293(4):1120-1137. PubMed ID: 29158255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel UCHL
    Song Z; Tu X; Zhou Q; Huang J; Chen Y; Liu J; Lee S; Kim W; Nowsheen S; Luo K; Yuan J; Lou Z
    Cell Death Dis; 2019 May; 10(6):398. PubMed ID: 31113933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Redox regulation of RAD51 Cys319 and homologous recombination by peroxiredoxin 1.
    Skoko JJ; Cao J; Gaboriau D; Attar M; Asan A; Hong L; Paulsen CE; Ma H; Liu Y; Wu H; Harkness T; Furdui CM; Manevich Y; Morrison CG; Brown ET; Normolle D; Spies M; Spies MA; Carroll K; Neumann CA
    Redox Biol; 2022 Oct; 56():102443. PubMed ID: 36058112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DAXX, as a Tumor Suppressor, Impacts DNA Damage Repair and Sensitizes BRCA-Proficient TNBC Cells to PARP Inhibitors.
    Shi Y; Jin J; Wang X; Ji W; Guan X
    Neoplasia; 2019 Jun; 21(6):533-544. PubMed ID: 31029033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BKM120 sensitizes BRCA-proficient triple negative breast cancer cells to olaparib through regulating FOXM1 and Exo1 expression.
    Li Y; Wang Y; Zhang W; Wang X; Chen L; Wang S
    Sci Rep; 2021 Feb; 11(1):4774. PubMed ID: 33637776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of DNA Replication Stress by CHK1 Leads to Chemoresistance Despite a DNA Repair Defect in Homologous Recombination in Breast Cancer.
    Meyer F; Becker S; Classen S; Parplys AC; Mansour WY; Riepen B; Timm S; Ruebe C; Jasin M; Wikman H; Petersen C; Rothkamm K; Borgmann K
    Cells; 2020 Jan; 9(1):. PubMed ID: 31963582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GLI1-targeting drugs induce replication stress and homologous recombination deficiency and synergize with PARP-targeted therapies in triple negative breast cancer cells.
    Mani C; Tripathi K; Omy TR; Reedy M; Manne U; Palle K
    Biochim Biophys Acta Mol Basis Dis; 2022 Feb; 1868(2):166300. PubMed ID: 34748904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination.
    Schultz N; Lopez E; Saleh-Gohari N; Helleday T
    Nucleic Acids Res; 2003 Sep; 31(17):4959-64. PubMed ID: 12930944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of homologous recombination with vorinostat synergistically enhances ganciclovir cytotoxicity.
    Ladd B; Ackroyd JJ; Hicks JK; Canman CE; Flanagan SA; Shewach DS
    DNA Repair (Amst); 2013 Dec; 12(12):1114-21. PubMed ID: 24231389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer.
    Chopra N; Tovey H; Pearson A; Cutts R; Toms C; Proszek P; Hubank M; Dowsett M; Dodson A; Daley F; Kriplani D; Gevensleben H; Davies HR; Degasperi A; Roylance R; Chan S; Tutt A; Skene A; Evans A; Bliss JM; Nik-Zainal S; Turner NC
    Nat Commun; 2020 May; 11(1):2662. PubMed ID: 32471999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in Expression of Key DNA Damage Repair Genes after Epigenetic-Induced BRCAness Dictate Synthetic Lethality with PARP1 Inhibition.
    Wiegmans AP; Yap PY; Ward A; Lim YC; Khanna KK
    Mol Cancer Ther; 2015 Oct; 14(10):2321-31. PubMed ID: 26294743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy.
    Mio C; Gerratana L; Bolis M; Caponnetto F; Zanello A; Barbina M; Di Loreto C; Garattini E; Damante G; Puglisi F
    Int J Cancer; 2019 Feb; 144(4):755-766. PubMed ID: 30259975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Depletion of DNA damage binding protein 2 sensitizes triple-negative breast cancer cells to poly ADP-ribose polymerase inhibition by destabilizing Rad51.
    Zhao L; Si CS; Yu Y; Lu JW; Zhuang Y
    Cancer Sci; 2019 Nov; 110(11):3543-3552. PubMed ID: 31541611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.